Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 4/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484654 | 0.90 | MEN1 (0.53) | MEN1KMT2AGAAPKMNPC1 | |
| SCHEMBL3484455 | 0.87 | TBXA2R (0.50) | TBXA2RMEN1KMT2AGAAPKM | |
| SCHEMBL3484062 | 0.83 | ERBB2 (0.46) | ERBB2SCN9A | |
| SCHEMBL3484468 | 0.76 | MEN1 (0.55) | TBXA2RMEN1KMT2AGAAPKM | |
| SCHEMBL24167691 | 0.76 | ALDH1A1 (0.45) | TBXA2RMEN1KMT2AGAAPKM | |
| SCHEMBL30879433 | 0.76 | ALDH1A1 (0.45) | TBXA2RMEN1KMT2AGAAPKM | |
| SCHEMBL1193081 | 0.76 | PDE7A (0.48) | TBXA2RMEN1KMT2AGAAPKM | |
| SCHEMBL30478690 | 0.76 | PDE7A (0.48) | TBXA2RMEN1KMT2AGAAPKM | |
| SCHEMBL29888161 | 0.75 | MEN1 (0.53) | ERBB2MEN1KMT2AGAAPKM | |
| SCHEMBL216106 | 0.75 | MEN1 (0.53) | ERBB2MEN1KMT2AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | ERBB2 1/4885TBXA2R 2025/4885SCN9A 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.